Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZhaoshen Li
About this trial
The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are:
Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy.
Participants will Provide post-operative cyst fluid specimens.
Eligibility criteria
Qualifiers
Subjects are ≥ 18 years old, regardless of gender;
Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;
Subjects voluntarily accepted radical resection of pancreatic cystic tumors;
Subjects or family members voluntarily sign the informed consent form for clinical research.
Disqualifiers
The excised sample does not contain cystic components, or the cystic fluid cannot be collected;
Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;
Receive antibiotic treatment within 1 week before operation;
Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;
Trial design
Treatments tested in this trial
- cfDNA methylation sequencing and proteome analysis
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Zhaoshen Li
Lead sponsor
Changhai Hospital
Sponsor institution
Oriental Hepatobiliary Surgery Hospital Affiliated to Naval Military Medical University
Collaborator
Zhejiang University
Collaborator
The First Affiliated Hospital of Nanchang University
Collaborator
West China Hospital
Collaborator
LanZhou University
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Peking University Cancer Hospital & Institute
Collaborator
First Hospital of China Medical University
Collaborator
First Affiliated Hospital of Guangxi Medical University
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborator
The Second Affiliated Hospital of Baotou Medical College
Collaborator
Shandong Province Third hospital
Collaborator
Source ClinicalTrials.gov